<p>Rubedo Life Sciences released Phase 1b clinical findings for RLS-1496 in patients with atopic dermatitis. The company claims four weeks of topical treatment produced a statistically significant mean reduction of 2.1 years in measured skin epigenetic age across 11 paired photoaged skin samples (p=0.0</p>